Trial Profile
Everolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2011
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 17 Jan 2011 New trial record
- 10 Jan 2011 The global trial, including the USA and other locations, is planned for later this year, according to an Abbott media release.